Novavax shares plunged 12.6%, its sharpest drop in four months, after announcing a $225 million debt refinancing and facing a Bank of America downgrade to 'Underperform' with a $7 target. Investors fear dilution and weak vaccine demand despite Sanofi covering most FDA study costs. Retail traders on Stocktwits stayed bullish, calling partnerships the key long-term catalyst.